1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Xilong Scientific Co., Ltd. Class A

Xilong Scientific Co., Ltd. Class A

SSZSE:002584
7.47
CNY
+0.09
(+1.22%)
-0.10EPS
5.55BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.42
4.42
4.43
5.14
5.89
5.7
6.06
9.7
10.07
10.41
12.76
13.92
12.62
13.52
Basic EPS, GAAP
0.1
0.16
0.16
0.17
0.16
0.12
0.07
0.1
0.35
0.15
0.06
0.11
-0.13
-0.1
Free Cash Flow per Basic Share
-0.17
0.01
0.06
-0.13
-0.1
-0.19
0.16
0.01
0.59
-0.87
-0.9
0.46
-0.05
- -
Dividend per Share
0.14
0.03
0.04
0.05
0.07
0.09
0.12
0.11
0.1
0.07
0.09
0.15
0.08
0.08
Book Value per Share
2.06
2.21
2.94
2.98
2.9
3.01
3.32
3.45
3.8
3.95
4.01
3.93
3.71
3.78
Tangible Book Value per Share
1.92
1.93
2.7
2.73
2.65
2.16
2.52
2.7
3.05
3.68
3.71
3.62
3.4
3.49
Basic Weighted Avg Shares
506
497
567
569
577
588
550
582
534
594
556
562
581
589
Sales/Revenue/Turnover
2,240
2,198
2,514
2,928
3,395
3,355
3,338
5,646
5,380
6,183
7,092
7,816
7,331
7,958
Operating Margin (%)
2.91
5.18
5.57
3.89
3.12
4.32
4.06
2.23
3.36
2.07
2.04
2.44
2.33
2.44
Depreciation Expense
18
21
26
31
34
36
37
19
35
44
49
58
76
- -
Net Income, GAAP
49
78
91
97
92
71
39
58
187
89
33
62
-75
-58
Effective Tax Rate (%)
18.12
17.93
19.92
18.06
14.82
8.16
24.63
21.16
3.82
14.64
19.41
12.86
- -
- -
Profit Margin (%)
2.17
3.53
3.61
3.31
2.72
2.1
1.15
1.03
3.48
1.44
0.47
0.79
-1.03
-0.73
Working Capital
580
422
1,016
846
879
854
928
1,187
1,307
1,345
1,260
1,300
1,265
1,180
LT Debt
- -
7
7
27
47
271
217
143
61
229
283
276
251
190
Total Equity
1,030
1,138
1,798
1,811
1,722
1,817
2,000
2,089
2,306
2,316
2,354
2,306
2,176
2,218
Return on Invested Capital (%)
3.49
5.72
5.52
4.34
4.55
2.58
1.25
2.17
6.72
2.79
1.07
2.36
- -
- -
Return on Capital (%)
4.62
6.4
5.62
5.42
5.47
5.1
2.87
3.25
7.92
4.16
2.35
2.93
- -
- -
Return on Common Equity (%)
4.7
7.26
6.42
5.59
5.37
4.08
2.08
2.94
8.82
3.93
1.43
2.66
-3.38
-2.57

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,032
1,123
1,189
LT Borrowings
243
240
186
LT Finance Leases
8
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
585
585
585
Market Capitalization
5,390
4,565
5,548

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,544
3,753
3,719
Cash, Cash Equivalents & STI
710
530
550
Accounts Receivable, Net
1,538
1,802
1,720
Inventories
647
690
721
Total Current Liabilities
2,278
2,505
2,539
Payables & Accruals
- -
- -
- -
ST Debt
1,032
1,123
1,189
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.06%
0.95%
-5.63%
Free Cash Flow
386.82%
873.93%
-111.96%
Net Income, GAAP
-4.64%
-6.08%
-222.2%
Sales/Revenue/Turnover
12.88%
5.79%
-6.21%
Total Cash Common Dividend
13.48%
0.78%
-42.59%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,935
2,016
2,039
1,826
7,816
2025
1,724
1,644
- -
2,007
7,331
2026
1,823
2,485
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.06
0.04
- -
0.11
2025
0.01
-0.14
- -
-0.02
-0.13
2026
0.02
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.04
0.04
0.06
0.15
2025
0.01
0.02
- -
0.02
0.08
2026
0.02
0.02
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ye Zhao
Full Time Employees
1,420
Sector
Process industries
Industry
Chemicals: specialty
Address
No. 2 Xilong Middle Street Guangzhou GD China 510530
IPO Date
May 24, 2011
Website
xilongs.com
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
Dow Inc. (NYSE:DOW)
Business
Xilong Scientific Co., Ltd. specializes in the research, development, production, and sale of chemical reagents and related products. The company offers a comprehensive range of chemical reagents including general chemical reagents such as ammonia water, sodium hydroxide, sulfuric acid, nitric acid, carbinol, and ethanol; printed circuit board (PCB) reagents; super clean high-purity chemical reagents; food additives; active pharmaceutical ingredients (APIs); pharmaceutical intermediates; wet electronic chemicals; diagnostic reagents; and chemical raw materials. It supplies these products primarily to industries including pharmaceuticals, biotechnology, agriculture, food processing, electronics, life sciences, environmental protection, and scientific research. The company also engages in the trading of chemical raw materials and glassware. Xilong supports markets across China and exports to North America, South America, Europe, Southeast Asia, Middle East, Africa, and Oceania. It operates multiple production facilities in China, with its main factory in Shantou, Guangdong Province. Founded in 1983 and headquartered in Guangzhou, China, Xilong is one of the largest and most professional chemical reagent manufacturers in the country and was the first chemical reagent company listed on the Shenzhen Stock Exchange in 2011. Recent major changes include strategic capital injections into its wholly owned subsidiaries Yunnan Yinghe New Energy Materials Co., Ltd., Guangzhou Xilong Chemical Co., Ltd., and Shanghai Xilong Chemical Co., Ltd., totaling approximately 209 million RMB in 2024 to enhance competitiveness and promote sustainable development. The company reported a significant revenue increase with net income growth forecast for 2024, reversing recent losses recorded in the first half of 2025. Xilong also focuses on strengthening R&D capabilities with over 50 staff dedicated to research and has advanced production lines specializing in PCB and ultra-clean high-purity reagents. The company maintains strict adherence to ISO 9001, ISO 14001, and OHSAS 18001 standards for quality, environmental, and safety management. Xilong's recent operational emphasis includes innovations in product development and expansion in energy and pharmaceutical-related chemical segments. It continues to play a critical role in supplying essential chemical materials for diverse high-technology industries and scientific research sectors.